Objectives: Peroxisome assembly disorders are genetic disorders characterized by biochemical abnormalities, including low docosahexaenoic acid (DHA). The objective was to assess whether treatment with DHA supplementation would improve biochemical abnormalities, visual function, and growth in affected individuals.
Peroxisome assembly disorders are a genetically heterogeneous group of disorders characterized by the disruption of peroxisomal protein importation. 1 The majority of these disorders result from an abnormality of PTS1 targeting and importation and are referred to as Zellweger spectrum disorder (ZSD). This disorder is seen in 1 per 50,000 births. 2 Clinically, individuals with ZSD have hypotonia, development delay, retinal degeneration, sensorineural hearing loss, and other organ system involvement. These are serious disorders, and many affected individuals die in infancy or childhood, although survival to adulthood is documented. 3 While genetically heterogeneous, the involvement of PTS1-mediated protein importation results in a characteristic set of biochemical abnormalities. The list of involved pathways is extensive but includes plasmalogen synthesis, long chain fatty acid degradation, and the synthesis of docosahexaenoic acid (DHA). 4 DHA is a polyunsaturated fatty acid that has been determined to be important in brain and retinal development. 5 Individuals with ZSD have been determined to be deficient in DHA, 6 but the exact role of this deficiency in the pathogenesis of the disorder is not known.
Preliminary studies 7, 8 demonstrated the ability to supplement DHA orally and increase the levels in the blood stream. Whereas other investigators 8 have reported improvement in the clinical status, we have noted that despite adequate supplementation in all patients studied in an open trial, the variation and severity of preexistent deficits made the experience difficult to interpret.
Our aim in this study was to assess the efficacy of DHA in improving visual function and physical growth through a double-blind, placebo-controlled, randomized trial. We also investigated the relation between DHA supplementation and biochemical peroxisomal measures, including plasma very long chain fatty acid (VLCFA) and red blood cell (RBC) plasmalogen levels.
METHODS Participants. Eligible participants were children aged 1 month to 10 years and diagnosed with Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease by characteristic biochemical profile, which includes increased VLCFAs, increased plasma phytanic acid, increased plasma pipecolic acid, decreased RBC plasmalogen, and decreased plasma DHA levels.
All participants were admitted to the Pediatric Clinical Research Unit of the Johns Hopkins Hospital, Baltimore, Maryland.
Objectives. Our primary hypothesis was that DHA supplementation improves visual function and physical growth (Class II evidence) in children affected with peroxisome assembly disorders. Our secondary hypothesis was DHA supplementation normalizes biochemical peroxisomal measures, including plasma VLCFA and RBC plasmalogen levels (Class II evidence).
Standard protocol approvals, registrations, and patient consents.
The study protocol was approved by the institutional review board, and individual written informed consents were obtained from patients' families.
Study design and interventions.
This was a randomized, double-blind, placebo-controlled trial conducted at a single center. Participants were randomly assigned to 2 interventions in a 1:1 ratio using a random number generator. Randomization was performed by the investigational pharmacy of Johns Hopkins Hospital. The treatment group received supplements of DHA and arachidonic acid (AA). Assigned treatments were mailed to patients' homes through the investigational pharmacy at Johns Hopkins Hospital; this pharmacy was the only unmasked entity. Neither the investigators nor the patients were aware of the treatment assignment during the trial period and until the evaluations were completed and analyzed.
It had been previously determined that in otherwise healthy premature infants, supplementation with DHA alone could result in decreased AA levels and decreased growth. We have shown that DHA supplementation with DHA ethyl ester did decrease AA levels significantly in children with peroxisomal disorders (data not shown), so we decided to supplement DHA and AA. This combination is presently used in infant formula supplementation.
The prepared treatment was a microencapsulated powder that contained DHA triglyceride (47% DHA) and AA triglyceride (46% AA). Placebo was similarly prepared soybean oil. Doses of these study medications were 100 mg/kg/d, which were based on previous open study experience. 9 This study medication could be mixed with food or infant formula. Both were similar in appearance and comparable in taste and smell. Treatment compliance was monitored by plasma DHA levels. Participants at the time of enrollment were instructed in a low-phytanic diet, mainly restricting whole milk consumption. The registered dietician was in regular contact with families to confirm adequate intake of nutrients. This study was undertaken and completed before the availability of commercial formulas that now routinely contain DHA with AA. Study agents were provided by Martek Biosciences Corporation (Columbia, MD).
Outcome. Evaluations included neurologic, biochemical, ophthalmologic, growth, and monitoring of hematologic and blood chemistry. Plasma VLCFA, and DHA and plasmalogen levels in RBCs were evaluated at baseline and 3, 6, 9, and 12 months. The remainders of the evaluations (described below) were performed at baseline and 1-year follow-up. The standard ratio of 18:0 dimethylacetals/18:0 in erythrocytes was used as a measure of plasmalogen. Serum VLCFA, DHA and erythrocyte plasmalogen assays were performed in the Peroxisome Diagnostic Laboratories of Kennedy Krieger Institution using standard methodologies. [10] [11] [12] Visual function was evaluated using electroretinogram (ERG). At baseline, ERGs were graded as a) extinguished, b) very low (Ͻ10 V), c) low (Ͻ50 V), or d) moderate (Ͼ50 V). At follow-up, patients' results were compared with their baseline examination data and were categorized as worse, no change, or improved.
Physical growth was evaluated by following the Z scores of weight and height over the course of the trial.
The primary outcome of the trial was change from baseline in visual function and physical growth during the 1-year follow-up period.
All of our patients received neurologic and neurodevelopmental evaluations as part of the study, but the decision was made to restrict analysis to quantitative outcomes. There was no unusual developmental event on subjective evaluations in any of the participants.
The pretrial anticipated rate of improvement in the visual function was 60% for the treatment group 8 and 20% for the control group. 2 Power calculations were based on the natural history data at Kennedy Krieger Institute. A sample of 22 subjects per group was required for 80% power and a level of significance of 0.05. Sample size was further inflated by 10% to address missing data or loss to follow-up. Power calculation was also performed for change in weight and height Z scores, before and after treatment with DHA. It was estimated that 25 patients in each group would provide more than 90% power to detect 1 SD change in Z scores of weight and height.
Statistical methods. Baseline characteristics were compared by randomized groups using t tests for continuous-level variables and 2 tests for proportions. Primary analyses were performed on 48 randomized participants based on intent-to-treat principle. The 2 test was used to compare ERG outcomes. Repeated-measures analysis of variance was used to evaluate the difference in aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, and change of weight and height from baseline to 1-year follow-up. The criterion for statistical significance was set at Յ0.05.
All analyses were performed using STATA version 8 (STATA Corp LP, College Station, TX).
RESULTS
Because peroxisomal disorders are rare, we informed all centers treating these patients about this study. A total of 51 patients were screened, and 50 of these were enrolled between February 1, 1997, and April 30, 2001 (period of 4 years 3 months). Twentyfive were randomly assigned to receive DHA, and 25 were randomly assigned to receive placebo. Two patients were excluded from study analysis when their diagnosis changed after complete biochemical analysis, which was performed during the baseline visit (both individuals had single enzyme disorders affecting peroxisomal ␤ oxidation). All 48 patients received at least 1 dose of study medication and were included in efficacy and safety analyses. The baseline characteristics of the 2 groups were similar, as shown in table 1. Three patients in the DHA group and 2 patients in the placebo group (10% of the enrolled participants) missed their follow-up visit and could not be contacted. Nine patients died during the course of the trial secondary to the natural progression of the disease. Eight of these 9 patients were diagnosed with ZS, and 1 was diagnosed Abbreviations: ALD ϭ adrenoleukodystrophy; DHA ϭ docosahexaenoic acid.
with NALD. The figure depicts the enrollment and progress of patients throughout the trial. The frequency of patients with improved ERG was similar in 2 groups, as shown in table 2. The treatment effect of DHA supplementation on other outcomes is also shown in table 2. DHA was well tolerated, and there was no serious adverse event reported that was conclusively related to interventions.
DISCUSSION
In this placebo-controlled, randomized trial among children with peroxisome as-sembly disorders, we found no overall effects of oral DHA supplementation on visual function, growth, or biochemical measures. We noted that oral supplementation increases DHA blood levels without any adverse effects. Surprisingly, visual function deteriorated in only 1 patient of each group who was able to return for follow-up; the rest either improved or stayed the same. Similarly, weight and height improved over time regardless of intervention. DHA supplementation had no significant impact on VLCFA or plasmalogen lev- Abbreviations: ALT ϭ alanine aminotransferase; AST ϭ aspartate aminotransferase; DHA ϭ docosahexaenoic acid.
After 1 year of follow-up, weight and height improved in both groups, and treatment effect of DHA was not significant. Plasma DHA levels were below normal in all patients at baseline (normal range 26.01-46.95 g/mL). C26:0 levels and C26:0/C22:0 ratios were increased in all patients at baseline (normal range C26:0 0.26 Ϯ 0.15 g/mL, C26:0/C22:0 0.01 Ϯ 0.004). DHA supplementation did not reduce the C26:0 levels. At baseline, plasmalogen levels (18:0 dimethylacetals/18:0 ratio) were low in both groups. DHA treatment did not affect the plasmalogen levels. ALT (U/L), AST (U/L), and total bilirubin (mg/dL) levels were not changed by DHA supplementation, and there was no treatment effect. Confidence intervals are 95% confidence intervals of difference in means between DHA and placebo groups. els, which were characteristic peroxisomal biochemical abnormalities in our patients. In previous open studies, 7, 8 it had been stated that DHA supplementation was associated with improvements in vision and growth of these children. In a similar fashion, we also noticed improvement in vision, weight, and height in both groups, but these effects were not related to DHA supplementation because they were present also in the untreated group. Additionally, unexplained biochemical improvements were also reported. Most likely these changes in VLCFAs and plasmalogens may reflect mild variations with age and survival. In light of these findings of maturational effects in untreated individuals, other alleged benefits, including changes in myelin, are suspect without a comparison group. 13 This study, in comparison with previous open trials, highlights the limitations of presuming to know the natural history of a rare disorder. It is apparent that the children who did not die during the study period maintained stable features and in some instances improved.
The limits of our study are that there was no uniformity in the genetic etiology of the affected children. It is possible that certain mild genotypes of particular PEX genes may receive more benefit from postnatal supplementation with DHA, but given the rarity of these conditions, such a limited study is not feasible. Similarly, the restricted sample size and variability in age of participants may have missed a small treatment effect, but prior open case reports did not limit their claims of efficacy, which were not shown to be valid here.
Unfortunately, therapies for peroxisomal disorders remain limited. Peroxisome assembly disorders involve multiple systems and have their onset during fetal development. Many of the pathologic features are set in motion at this developmental stage, and any therapy instituted after birth is unlikely to offset this. Although supplementation with DHA is without significant adverse effect in this population, its therapeutic use cannot be endorsed at this time.
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